Back to results
US 2007/0191490 A1Published application
Withacnistin compounds for treatment of cancer
OwnerSaid Sebtiinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerSaid Sebtiinventor
Estimating the term…
The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing one or more withacnistin compounds, or a pharmaceutically acceptable salt or derivative thereof. In one embodiment, the subject invention concerns a composition comprising a mixture of withacnistin, 3-methoxy-2,3-dihydrowithacnistin, and 3-ethoxy-2,3 -dihydrowithacnistin, or a salt or derivative of any of the foregoing. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering one or more withacnistin compounds, or a pharmaceutically acceptable salt or derivative thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the STAT3 signaling pathway in vitro or in vivo using one or more withacnistin compounds, or a pharmaceutically acceptable salt or derivative thereof.
A method for treating cancer in a patient, comprising administering withacnistin, or a pharmaceutically acceptable salt or analog thereof, to a patent in need of treatment.
A pharmaceutical composition comprising isolated withacnistin, and a pharmaceutically acceptable carrier or diluent.
A method for preparing a pharmaceutical composition, comprising isolating withacnistin from a plant and combining the isolated withacnistin with a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition containing a therapeutically effective amount of withacnistin or a physiologically acceptable salt or prodrug thereof, in admixture with one, or more, pharmaceutically acceptable carriers, adjuvants, diluents and/or excipients.
A pharmaceutical composition comprising a co-crystal comprising withacnistin and a co-crystal former.
A method for treating cancer in a patient, comprising administering a pharmaceutical composition comprising a P-STAT inhibitor to the patient, the P-STAT inhibitor consisting essentially of withacnistin.
A method for inhibiting the growth of cancer cells in a patient, comprising administering a pharmaceutical composition comprising a P-STAT inhibitor to the patient, the P-STAT inhibitor consisting essentially of withacnistin, resulting in inhibited cancer growth.
A method for treating cancer in a patient, comprising administering a pharmaceutical composition comprising only one withacnistin compound, wherein the withacnistin compound is withacnistin or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.